The United States Food and Drug Administration (FDA) has taken steps to enhance patient education on breast implants, including recalling specific devices and revising screening recommendations for silicone implant rupture. This response comes as more information about the risks associated with breast implants emerges. Radiologists are urged to stay informed about FDA guidelines, be knowledgeable about various implant types, breast reconstruction methods (e.g., the use of acellular dermal matrix), and the multimodal imaging techniques for observing implants and their complications. A critical update is the FDA’s acceptance of ultrasound (US) as a viable screening method for detecting silicone implant rupture, marking a significant shift from previous guidelines. This change, along with the need to differentiate between FDA recommendations and the American College of Radiology Appropriateness Criteria, underscores the evolving landscape of breast implant management and the importance of radiologists’ role in ensuring patient safety.